/
Neurology
Amyotrophic Lateral Sclerosis
57
Pipeline Programs↗
109
Active Trials↗
76
Companies Involved↗
Amyotrophic Lateral Sclerosis is a moderately active landscape with 57 programs across 76 companies. The most active players are Amylyx Pharmaceuticals Inc., Biogen, Ionis Pharmaceuticals. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical22
Phase 115
Phase 214
Phase 36
Approved
No programs
Analysis
Modality Breakdown
98%
Small molecule
43 of 44 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 44 classified programs, each share of the total. Modality classified for 86% of 57 pipeline programs.
Analysis
Trial Status
322
clinical trials
Completed147 · 46%
Recruiting51 · 16%
Active, not recruiting30 · 9%
Terminated29 · 9%
Not yet recruiting25 · 8%
Unknown status17 · 5%
Other23 · 7%
Clinical Trials
Trial Activity
322 trials
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial Evaluating the Safety, Efficacy, and Pharmacokinetic Characteristics of TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
Recruiting·TTalengen Institute of Life Sciences, Shenzhen, P.R. China.·Preclinical·NCT06726577·60 enrolled
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
Recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT07204977·30 enrolled
Page 1 of 22
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)